Effects of implanting a long-term left ventricle assist device on post-transplant outcomes.


Journal

The International journal of artificial organs
ISSN: 1724-6040
Titre abrégé: Int J Artif Organs
Pays: United States
ID NLM: 7802649

Informations de publication

Date de publication:
Jan 2021
Historique:
pubmed: 25 4 2020
medline: 15 5 2021
entrez: 25 4 2020
Statut: ppublish

Résumé

An increasing number of patients are receiving left ventricle assist devices as a bridge to heart transplantation. The aim of this study was to determine the difference between patients who received transplants from a left ventricle assist device and those who underwent heart transplantation without a prior left ventricle assist device implantation. The study included patients who underwent heart transplantation in our institute between January 2010 and November 2018. The following clinical variables were evaluated: donor characteristics, patient's pre-transplant demographical data, post-transplant data, and patient survival. Cardiac allograft vasculopathy progression was prospectively examined (after 1 month and 12 months after heart transplantation) by coronary optical coherence tomography. We were interested in the difference in 1- and 5-year survival between the left ventricle assist device and non-left ventricle assist device groups. A total of 248 patients were identified; out of them, 48 patients received a left ventricle assist device before heart transplantation, whereas 200 had transplants with no prior left ventricle assist device implantation. There were no significant differences in any donor characteristics. The mean duration of cardiopulmonary bypass time in the non-left ventricle assist device group was 156 versus 175 min in the left ventricle assist device group ( Our results indicate that patients undergoing heart transplantation from left ventricle assist devices suffer significantly more from intraoperative and post-operative complications; however, only insignificant cardiac allograft vasculopathy progression and survival differences between the two groups were observed.

Sections du résumé

BACKGROUND BACKGROUND
An increasing number of patients are receiving left ventricle assist devices as a bridge to heart transplantation. The aim of this study was to determine the difference between patients who received transplants from a left ventricle assist device and those who underwent heart transplantation without a prior left ventricle assist device implantation.
MATERIAL AND METHODS METHODS
The study included patients who underwent heart transplantation in our institute between January 2010 and November 2018. The following clinical variables were evaluated: donor characteristics, patient's pre-transplant demographical data, post-transplant data, and patient survival. Cardiac allograft vasculopathy progression was prospectively examined (after 1 month and 12 months after heart transplantation) by coronary optical coherence tomography. We were interested in the difference in 1- and 5-year survival between the left ventricle assist device and non-left ventricle assist device groups.
RESULTS RESULTS
A total of 248 patients were identified; out of them, 48 patients received a left ventricle assist device before heart transplantation, whereas 200 had transplants with no prior left ventricle assist device implantation. There were no significant differences in any donor characteristics. The mean duration of cardiopulmonary bypass time in the non-left ventricle assist device group was 156 versus 175 min in the left ventricle assist device group (
CONCLUSION CONCLUSIONS
Our results indicate that patients undergoing heart transplantation from left ventricle assist devices suffer significantly more from intraoperative and post-operative complications; however, only insignificant cardiac allograft vasculopathy progression and survival differences between the two groups were observed.

Identifiants

pubmed: 32329386
doi: 10.1177/0391398820914626
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-45

Auteurs

Helena Bedanova (H)

Center of Cardiovascular and Transplant Surgery Brno, Brno, Czech Republic.

Michal Pazdernik (M)

Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Milan Sonka (M)

The University of Iowa, Iowa City, IA, USA.

Chen Zhi (C)

The University of Iowa, Iowa City, IA, USA.

Jan Krejci (J)

Department of Sports Medicine and Rehabilitation, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Marie Novakova (M)

Department of Sports Medicine and Rehabilitation, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Petr Dobsak (P)

Department of Sports Medicine and Rehabilitation, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Petr Nemec (P)

Center of Cardiovascular and Transplant Surgery Brno, Brno, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH